Expanded Clinical Evaluation of Lovastatin (EXCEL) study results. I. Efficacy in modifying plasma lipoproteins and adverse event profile in 8245 patients with moderate hypercholesterolemia
作者： Reagan H Bradford , Charles L Shear , Athanassios N Chremos , Carlos Dujovne , Maria Downton
DOI: 10.1001/ARCHINTE.151.1.43
关键词: Surgery 、 Medicine 、 Clinical trial 、 Placebo 、 Cholesterol 、 Internal medicine 、 Lovastatin 、 Adverse effect 、 Liver function tests 、 Randomized controlled trial 、 Chemotherapy
摘要: In the Expanded Clinical Evaluation of Lovastatin (EXCEL) Study, a multicenter, double-blind, diet- and placebo-controlled trial, we evaluated efficacy safety lovastatin in 8245 patients with moderate hypercholesterolemia. Patients were randomly assigned to receive placebo or at dosage 20 mg once daily, 40 twice daily for 48 weeks. produced sustained, dose-related ( P Arch Intern Med . 1991;151:43-49)
ama-assn.org
sci-hub.st 参考文章(21)
H. Leon Harter, Order statistics and their use in testing and estimation Aerospace Research Laboratories; for sale by the Supt. of Docs., U.S. Govt. Print. Off., Washington. ,(1969)
Alan M Laties, Charles L Shear, Erik A Lippa, A Lawrence Gould, Hugh R Taylor, Dennis P Hurley, Wendy P Stephenson, Edwin U Keates, Mary Ann Tupy-Visich, Athanassios N Chremos, None, Expanded clinical evaluation of lovastatin (EXCEL) study results II. Assessment of the human lens after 48 weeks of treatment with lovastatin The American Journal of Cardiology. ,vol. 67, pp. 447- 453 ,(1991) , 10.1016/0002-9149(91)90002-3
John A. Oates, Alastair J.J. Wood, Scott M. Grundy, HMG-CoA reductase inhibitors for treatment of hypercholesterolemia. The New England Journal of Medicine. ,vol. 319, pp. 24- 33 ,(1988) , 10.1056/NEJM198807073190105
Jonathan A Tobert, Charles L Shear, Athanassios N Chremos, Geraldine E Mantell, None, Clinical experience with lovastatin The American Journal of Cardiology. ,vol. 65, pp. 23- 26 ,(1990) , 10.1016/0002-9149(90)91251-Z
R Peto, M C Pike, P Armitage, N E Breslow, D R Cox, S V Howard, N Mantel, K McPherson, J Peto, P G Smith, Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples. British Journal of Cancer. ,vol. 35, pp. 1- 39 ,(1977) , 10.1038/BJC.1977.1
Jonathan A. Tobert, Efficacy and long-term adverse effect pattern of lovastatin American Journal of Cardiology. ,vol. 62, ,(1988) , 10.1016/0002-9149(88)90004-5
Jeffrey M. Hoeg, 3-Hydroxy-3-Methylglutaryl—Coenzyme A Reductase Inhibitors in the Treatment of Hypercholesterolemia JAMA: The Journal of the American Medical Association. ,vol. 258, pp. 3532- 3536 ,(1987) , 10.1001/JAMA.1987.03400240064025
N. Burgess Record, Lovastatin vs Cholestyramine Therapy for Primary Hypercholesterolemia JAMA: The Journal of the American Medical Association. ,vol. 260, pp. 3591- 3591 ,(1988) , 10.1001/JAMA.1988.03410240048026
Sidney J. Cutler, Fred Ederer, Maximum utilization of the life table method in analyzing survival Journal of Chronic Diseases. ,vol. 8, pp. 699- 712 ,(1958) , 10.1016/0021-9681(58)90126-7
A. W. Alberts, J. Chen, G. Kuron, V. Hunt, J. Huff, C. Hoffman, J. Rothrock, M. Lopez, H. Joshua, E. Harris, A. Patchett, R. Monaghan, S. Currie, E. Stapley, G. Albers-Schonberg, O. Hensens, J. Hirshfield, K. Hoogsteen, J. Liesch, J. Springer, Mevinolin: a highly potent competitive inhibitor of hydroxymethylglutaryl-coenzyme A reductase and a cholesterol-lowering agent. Proceedings of the National Academy of Sciences of the United States of America. ,vol. 77, pp. 3957- 3961 ,(1980) , 10.1073/PNAS.77.7.3957